8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

________________

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported) – March 7, 2008

________________________

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

_____________________

Pennsylvania	1-8036	23-1210010
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)
101 Gordon Drive, PO Box 645, Lionville, PA		19341-0645
(Address of principal executive offices)		(Zip Code)

610-594-3319

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or address, if changed since last report)

____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On March 7, 2008, West Pharmaceutical Services, Inc. (the “Company”) issued a press release announcing that the Company will conduct a live webcast of its Investor Day event on Thursday, March 13, 2008 from 8:30 a.m. to approximately 11:30 a.m. Eastern Time. The event will be held at the Grand Hyatt Hotel in New York, New York. The following members of management will be presenting at the event:

Don Morel, Chairman and Chief Executive Officer

Steve Ellers, President and Chief Operating Officer

Mike Schaefers, Director of Marketing, Europe/Asia Pacific

John Paproski, Vice President, Innovation

Bernie Lahendro, Vice President and General Manager, Daikyo Crystal Zenith

During the event, management will discuss further its 2008 guidance and five-year outlook for the business. Management will cover the following points regarding expected financial performance over the five-year period:

•     Average annual sales growth of between 7% and 9%, excluding acquisitions

•     Average annual operating profit growth of between 10% and 12%

The information in this report (including Exhibit 99.1 and 99.2) is being furnished pursuant to Item 7.01 Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act.

A copy of the Company’s presentation from the Investor Day will be available for 30 days through the Investor link at the Company’s website, http://www.westpharma.com and is also attached hereto as Exhibit 99.1. A copy of the press release is attached hereto as Exhibit 99.2. Both Exhibits are incorporated herein by reference.

Safe Harbor Statement

This Form 8-K contains forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are based on management's beliefs and assumptions, current expectations, estimates and forecasts. Statements that are not historical facts, including statements that are preceded by, followed by, or that include, words such as "estimate," "expect," "intend," "believe," "plan," "anticipate" and other words and terms of similar meaning are forward-looking statements. West's estimated or anticipated future results, product performance or other non-historical facts are forward-looking and reflect our current perspective on existing trends and information.

Many of the factors that will determine the Company's future results are beyond the ability of the Company to control or predict. These statements are subject to known or unknown risks or uncertainties, and therefore, actual results could differ materially from past results and those expressed or implied in any forward-looking statement. You should bear this in mind as you

consider forward-looking statements. We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.

Important factors that may affect future results include, but are not limited to, the following:

Revenue and profitability:

-- sales demand and our ability to meet that demand;

-- competition from other providers in the Company's businesses, including

customers' in-house operations, and from lower-cost producers in

customers' in-house operations, and from lower-cost producers in

emerging markets, which can impact unit volume, price and

profitability;

-- customers' changing inventory requirements and manufacturing plans that

alter existing orders or ordering patterns for the products we supply

to them;

-- the timing, regulatory approval and commercial success of customer

products that incorporate our products, including relevant third-party

reimbursement for prescription products, medical devices and components

and medical procedures in which those products are employed or

consumed;

-- average profitability, or mix, of products sold in any reporting

period;

-- maintaining or improving production efficiencies and overhead

absorption;

-- the timeliness and effectiveness of capital investments, particularly

capacity expansions, including the effects of delays and cost increases

associated with construction, availability and cost of capital goods,

and necessary internal, governmental and customer approvals of planned

and completed projects, and the demand for goods to be produced in new

facilities;

-- dependence on third-party suppliers and partners, including our

Japanese partner Daikyo Seiko, Ltd.;

-- the availability and cost of skilled employees required to meet

increased production, managerial, research and other needs of the

Company, including professional employees and persons employed under

collective bargaining agreements;

-- interruptions or weaknesses in our supply chain, which could cause

delivery delays or restrict the availability of raw materials and key

bought-in components and finished products;

-- raw-material price escalation, particularly petroleum-based raw

materials, and our ability to pass raw-material cost increases on to

customers through price increases;

-- claims associated with product quality, including product liability,

and the related costs of defending and obtaining insurance indemnifying

the Company for the cost of such claims;

Other Risks:

-- the cost and progress of development, regulatory approval and marketing

of new products as a result of the Company's research and development

efforts;

-- the defense of self-developed or in-licensed intellectual property,

including patents, trade and service marks and trade secrets;

-- dependence of normal business operations on information and

communication systems and technologies provided, installed or operated

by third parties, including costs and risks associated with planned

upgrades to existing business systems;

-- the relative strength of the U.S. dollar in relation to other

currencies, particularly the Euro, British Pound, and Japanese Yen;

-- changes in tax law or loss of beneficial tax incentives;

-- the conclusion of unresolved tax positions consistent with currently

expected outcomes;

-- the timely execution and realization of savings anticipated by the

restructuring plan for certain operations and functions of The Tech

Group, announced in December 2007;

and other risks and uncertainties detailed in West's filings with the Securities and Exchange Commission, including our Form 10-K filed with the SEC on February 29, 2008. You should evaluate any statement in light of these important factors.

Item 9.01 Financial Statement and Exhibits.

(d)	Exhibits
	Exhibit #	Description
	99.1	West Pharmaceutical Services, Inc. presentation slides.
	99.2	West Pharmaceutical Services, Inc. Press Release, dated March 7, 2008.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

WEST PHARMACEUTICAL SERVICES, INC.

/s/ John R. Gailey III

John R. Gailey III

Vice President, General Counsel and Secretary

March 12, 2008

EX-99

Investor Day 2008

Don Morel

Chairman and Chief Executive Officer

Agenda and Participants

Welcome and IntroductionDon Morel

Market OverviewMike Schaefers

Growth PlatformsJohn Paproski

Daikyo Crystal Zenith Platform Bernie Lahendro

                                                   Break

Operations OverviewSteve Ellers

Long Term Outlook and SummaryDon Morel

Q&A Mike Anderson

Certain statements in the following slides and certain statements that may be made by management of the Company orally during this
presentation contain some forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, that are based on management’s plans and assumptions.  Such statements
give our current expectations or forecasts of future events; they do not relate strictly to historical or current facts. We have tried, wherever
possible, to identify such statements by using words such as “estimate,” “expect,” “intend,” “believe,” “plan,” “anticipate” and other words
and terms of similar meaning in connection with any discussion of future operating or financial performance or condition.  We cannot
guarantee that any forward-looking statement will be realized. If known or unknown risks or uncertainties materialize, or if underlying
assumptions are inaccurate, actual results could differ materially from past results and those expressed or implied in any forward-looking
statement.  You should bear this in mind as you consider forward-looking statements. We undertake no obligation to publicly update forward-
looking statements, whether as a result of new information, future events or otherwise.

Important factors that may affect future results include the following: Sales demand and our ability to meet that demand; competition from
other providers in the Company’s businesses, including customers’ in-house operations, and from lower-cost producers in emerging markets,
which can impact unit volume, price and profitability; customers’ changing inventory requirements and manufacturing plans that alter existing
orders or ordering patterns for the products we supply to them; the timing, regulatory approval and commercial success of customer
products that incorporate our products, including relevant third-party reimbursement for prescription products, medical devices and
components and medical procedures in which those products are employed or consumed;  average profitability, or mix, of products sold in
any reporting period; maintaining or improving production efficiencies and overhead absorption; the timeliness and effectiveness of capital
investments, particularly capacity expansions, including the effects of delays and cost increases associated with construction, availability
and cost of capital goods, and necessary internal, governmental and customer approvals of planned and completed projects, and the demand
for goods to be produced in new facilities; dependence on third-party suppliers and partners, including our Japanese partner Daikyo Seiko,
Ltd.; the availability and cost of skilled employees required to meet increased production, managerial, research and other needs of the
Company, including professional employees and persons employed under collective bargaining  agreements; interruptions or weaknesses in
our supply chain, which could cause delivery delays or restrict the availability of raw materials and key bought-in components and finished
products; raw-material price escalation, particularly petroleum-based raw materials, and our ability to pass raw-material cost increases on to
customers through price increases; claims associated with product quality, including product  liability, and the related costs of defending and
obtaining insurance indemnifying the Company for the cost of such claims; the cost and progress of development, regulatory approval and
marketing of new products as a result of the Company’s research and development efforts; the defense of self-developed or in-licensed
intellectual property, including patents, trade and service marks and trade secrets; dependence of normal business operations on information
and communication systems and technologies provided, installed or operated by third parties, including costs and risks associated with
planned upgrades to existing business systems; the relative strength of the U.S. dollar in relation to other currencies, particularly the Euro,
British Pound, and Japanese Yen; changes in tax law or loss of beneficial tax incentives; the conclusion of unresolved tax positions
consistent with currently expected outcomes; the timely execution and realization of savings anticipated by the restructuring plan for certain
operations and functions of The Tech Group, announced in December 2007; and,

Other risks and uncertainties detailed in West’s filings with the Securities and Exchange Commission, including our Registration Statement
on Form 10-K filed with the SEC on February 29, 2008.  You should evaluate any statement in light of these important factors.

Safe Harbor Statement: Forward Looking Statements

Trademarks: All trademarks and registered trademarks used in this report are the property of West Pharmaceutical Services,
Inc., in the United States and other jurisdictions, unless otherwise noted.

Founded in 1923

HQ in Lionville, PA

Company Overview

Who we are

World’s premier manufacturer
of components and systems
for injectable drug delivery

Closure systems and prefillable
syringe components

Components for disposable systems

Devices and device sub-assemblies

Safety and administration systems

Record 2007 sales $1.02 billion

Market cap $1.3 billion

Diverse, Stable Customer Base

Company Estimated Market Share: 70% in Pharma; 70% in Device; 95% in
Biotech

West’s Competitive Advantage

World class technical and regulatory support

Global supply chain stability – multiple site sourcing

Protected IP: West’s components and systems

Unmatched experience/expertise: drug - material interface

Regulatory barrier to entry:  NDA and ANDA filing must include reference to
all packaging/components in contact with the drug

1.

West Drug Master File (DMF) 1546 is confidential

2.

West DMF includes functionality data (multi-year studies)

3.

All primary package changes require new stability/functionality
studies for new filing

Engineering expertise in high-volume manufacturing and assembly

($ millions)

Strong Sales Growth

          Existing Business

          Acquisitions

$107

$227

$797

$223

Global
Revenue
Breakdown

Based on 2007 sales
of approx $1 billion

South America:

$55.3 million

(5%)

North America:
$496.4 million

(49%)

Europe:  

$430.6 million

(42%)

Asia/Pacific:

$37.8 million

(4%)

Our Long Term Objectives

Build on our global competitive advantages

to create multiple platforms

for sustainable growth

Four Strategic Growth Platforms

Injectable Container Solutions

Prefillable Syringe Systems

Advanced Injection Systems

Safety & Administration Systems

Future Growth Drivers

Aging population creates an increasing number of patients with chronic
illnesses such as diabetes and cancer

Biologic drug growth and a resurgence in vaccine research

Demand for ultra clean silicone free packaging and delivery systems

China, India economic growth and growing demand for advanced
healthcare

Point-of-care shift: Hospital    Specialty Clinic    Home

Convergence of the primary container and delivery device

West migration from component production to device systems

Tech business model shift to proprietary products

Source:  Datamonitor

Convergence of Primary Containers
and Delivery Systems

Disposable

Syringe-based

Auto Injectors

Traditional Injection
System

Components for
Pen System Applications

Our Long-Term Objectives

Build on our global competitive advantages to create
multiple platforms for sustainable growth

Undergo selective geographic expansion

Continued investment in innovation and new manufacturing
technology

Five-year financial goals:

Average annual sales growth 7-9%

Average annual operating profit growth 10-12%

Mike Schaefers, Ph.D.

Vice President of Marketing, Europe

Global Pharmaceutical
Market Update

Global pharmaceutical market predicted to increase by 5-6% in
value in 2008 vs. 6-7% in 2007 driven by:

Aging populations

Strong economies

Introduction of new products

Geographic expansion

Patent expirations ($16 billion in 2007, $12 billion in 2008)

Reimbursement issues

Strong generic competition

IMS Global Insight Nov. 2007, Drug Benefits News, Nov. 2007

Global Pharmaceutical Market Update

Geographic expansion

Growth in emerging markets (China, India, Brazil, Turkey, Russia) accelerated at
12-13%

Trend toward specialty products vs. former mass market approach (i.e.
oncology vs. cardiovascular)

Specialty products expected to grow 14-15% in 2008

80% of the 29 new innovative medicines expected to launch in 2008 will be
specialist products

Global pharmaceutical packaging market growing 6.5% annually to 2011

IMS Global Insight Nov. 2007

Global Pharmaceutical Market Update

Paradigm shift in the pharmaceutical world

Fewer new drugs being launched!

FDA approved 60 new drugs between 2005-2007 (NME, novel biologics)
vs. 60 new drugs approved in 1996 alone

Agencies move towards risk assessment based approval process

Limited claims for newly approved drugs

More black box warnings

More clinical evidence required

FDA, The RPM Report; IMS Global Insights, Nov. 2007

Global Pharmaceutical Market Update

Paradigm shift in the pharmaceutical world

Drug makers cut back costs

Workforce

Inventory

Lean programs

Supply chain programs

Sourcing costs

Companies increase R&D spend and fill pipelines through M&A activities
(mainly biotech)

FDA, The RPM Report; IMS Global Insights, Nov. 2007

Global Pharmaceutical Market Update

Pharma/biotech customer trends

Integration of container/closure system into delivery system

Reduction of drug waste and improved operational throughput

High quality packaging to ensure drug stability

Value-added devices and systems for product/brand differentiation

Secure packaging

Global Pharmaceutical Market Update

Patient/caregiver trends

Point of care shift

Hospital    specialty clinic/physician    home

Dosage form migration

Increase patient compliance rates through enhanced application systems
i.e. safety systems, pens, auto-injectors

Patient convenience

Ease of use

Minimized pain

Increased focus on healthcare worker, patient safety

Global Pharmaceutical Market Update

Top therapeutic categories

Increasing number of patients with chronic illnesses such as diabetes,
cancer, AIID (RA, MS, etc.)

Resurgence of vaccine market

Emergence of high-value therapeutic vaccines

New technologies and delivery methods

Pandemic concerns

Top therapeutic categories (annual growth 05-10)

Oncology+ 15%

Diabetes+  9%

AIID+ 10%

Vaccines+ 15%

Pharmaceutical & Diagnostic Innovation, 2006 Vo. 4, No. 10,IMS Global Insights, Nov. 2007

Global Pharmaceutical Market Update

Top therapeutic categories

Injectable products currently account for ~15% of global drug delivery
market

Significant growth expected through above mentioned therapeutic
categories

High number of injectable products in pipelines

Biologic drugs represent the fastest growing segment in injectable
pharma market (13% CAGR through 2010)

Arrowhead Publishers; Datamonitor

Global Pharmaceutical Market Update

Strategic Growth Platforms

Therapeutic Targets and

West’s Strategic Growth Platforms

Percentage of injectable products by therapeutic
category and biological injectables

(awaiting approval and in clinical trials in US – all forms)

West’s Therapeutic Targets

West’s Therapeutic Targets

Rationale

Current presence in targeted categories/ segments

Future annual growth rates per therapeutic category

Number of products in pipeline per therapeutic category

Percentage of injectable products in pipeline

Need for high-value products and enhanced packaging systems

Growth opportunities through advanced application and administration
systems

Therapeutic Targets and West Strategic Platforms

A Perfect Match

High value products for container
closures systems

Enhanced packaging systems

Advanced application and
administration systems

Needle safety systems

Stability of demanding pharma-
ceuticals/biopharmaceuticals

Need for product/brand differentiation

Secure and tamper evident
packaging (ID, anticounterfeiting)

Healthcare worker/patient safety

Trend towards self-administration

Improved patient compliance

West Strategic Platform Offerings

Therapeutic Target Requirements

Four Strategic Growth Platforms

Injectable Container Solutions

Prefillable Syringe Systems

Advanced Injection Systems

Safety & Administration Systems

Injectable Container Solutions

Prefillable Syringe Systems

Unique silicone-free syringe systems for demanding
biopharmaceuticals

Daikyo Crystal Zenith RU syringes

Daikyo Crystal Zenith is a registered trademark of Daikyo Seiko, Ltd.

Safety and Administration Systems

West´s reconstitution, administration and safety systems

Project Orion

MixJect

West Advanced Injection Systems

Syringe and cartridge-based autoinjector systems

Customer Account Penetration for
Strategic Platform Products

Secondary

Top Therapeutic Categories
and West’s Position

Westar RS/RU

Westar Lined Seals RS

Envision

VeriSure

Safety & Administration Systems

Advanced Injection Systems

Stability of biotechnologically derived
insulin drugs

High-quality container/closure
systems

Ease of use

Suitability for home administration

Switch from vial/syringe combinations to
pen injectors

West Offerings

Requirements

Diabetes/Insulin

Examples of West
Participation in Insulin Market

Top Therapeutic Categories
and West’s Position

FluroTec stoppers and plungers

Envision

VeriSure

Westar RS/RU

Daikyo Crystal Zenith RU syringe

Safety & Administration Systems

Advanced Injection Systems

High-quality packaging for stability of high
value therapeutic vaccines

Trend towards prefillable syringe
applications

Healthcare worker and patient safety

Minimized pain

Advanced delivery methods

West Offerings

Requirements

Vaccines

Top Therapeutic Categories
and West’s Position

FluroTec stoppers and plungers

Westar RS/RU

Envision

VeriSure

Daikyo Crystal Zenith RU syringe

Safety & Administration Systems

Advanced Injection Systems

Stability of demanding pharmaceutical/
biopharmaceutical compounds

Need for silicone-oil-free packaging

Reduction of drug waste

Break resistant packaging

Trend towards self-administration

Healthcare worker safety

Patient compliance

West Offerings

Requirements

Oncology/Hematology

Top Therapeutic Categories
and West’s Position

FluroTec stoppers and plungers

Westar RS/RU

Westar lined seals RS

Envision

VeriSure

Daikyo Crystal Zenith RU syringe

Safety & Administration Systems

Advanced injection systems

Stability of demanding biopharmaceutical
compounds

Reduction of drug waste

Need for silicone-oil-free packaging

Trend towards prefillable syringe
applications

Trend towards self-administration

Ease of use and patient compliance

Product / brand differentiation

West Offerings

Requirements

Autoimmune (RA, MS, AIID)

Generics

Are generics/biogenerics a threat for West?

West's Generic/Biogeneric Strategy

$12 billion of brand name drugs will go generic in 2008

West addresses challenge through multiple activities

Focus on therapeutic targets (specialty injectable drugs) growing faster than any
other category

Proactive support of lifecycle management activities at pharma/biotech
companies

Product/brand differentiation through innovative packaging, application and
administration systems

West´s Generic/Biogeneric Strategy

West addresses challenge through multiple activities

Growth opportunities through generic/biogeneric companies by
addressing their drug packaging needs

Primarily using originator’s container/closure system

Frequent outsourcing of value-added services to suppliers

Biogenerics forced to offer application and delivery systems

Summary

Major programs directly address market needs

Focus on strongly growing therapeutic categories diabetes/insulin,
vaccines, oncology and AIID

Importance of injectable and biological products within these categories

Growing need for high value container/closure and packaging systems

Growth opportunities through advanced application and administration
systems

Perfect match between requirements of targeted therapeutic categories
and West strategic platforms

Growth opportunities through generic/biogeneric markets

John Paproski

Vice President, Innovation

Growth Platforms

Innovation Focus
Bring unique value added solutions to the growing need
for combining injectable drug containers
with delivery systems

For 2008

Prepare three major products for broad market
introduction

Q2 – Ready-to-Use Daikyo Crystal Zenith luer lock syringe system

Q3 – Disposable auto injector for prefillable syringes

Q4 – Orion prefillable syringe safety system

Injectable Pharma Market Needs
Patient/Caregiver Focused

Increasing patient compliance rates

Patient and clinician convenience

Minimize pain and needle fear

Healthcare worker and patient safety

Sharps exposure

Blood-borne pathogen transmission (HIV, Hepatitis)

Unintended drug exposure

Home and self-administration

Provide cost effective reimbursement

Injectable Pharma Market Needs
Pharma Company Focused

Improve drug stability

Reduce drug waste

Integrate with existing filling operations

Reliable supply

Differentiate brands

Enabling delivery methods

Secure packaging

Risk mitigation

Outsourcing non-core competencies

West Innovation Model

Creating proprietary products that serve
our existing injectable customers

Regulatory hurdles for our customers

Slow time to market

Long product lives

Patent protected

Operate like start-up business units

Manufactured primarily by The Tech Group
or our partner, Daikyo

Provide high-value system solutions

West Sources of Innovation

Entrepreneurs

In-license intellectual property

Acquire small companies

Established products

Knowledgeable people

Intellectual property

Internal idea development

Innovation Spending

$ millions

Strategic Platforms: Target Markets

$1.5B

4%

9B

Injectable Containers

$1.5B

11%

5.2B

Safety &

Administration

$210M

8-12%

70M

Advanced Injection
Systems

$900M

8-12%

1.8B

Prefilled Syringe

Total Market

Sales

CAGR

(Unit)

Total
Market

Units

Strategic

Platform

Injectable Container Solutions

Market focus: high-value drugs

Drug stability

Reduced waste

Universal processing and filling

West innovations

Ready-to-Use Daikyo Crystal Zenith vial
system

Ready-to-Use Daikyo Crystal Zenith bulk
bio processing containers

Advanced Injection Systems

Market focus: high-value drugs

Self administration

Home administration

Use standard prefillable syringes

West innovations

Disposable auto-injector: Q3 2008

Advanced Injection SystemsSingle Use: Disposable Auto Injector for Staked Needle PFS

Utilizes 1ml long prefilled syringe format

Staked needle with rigid needle shield

Glass or CZ compatible

Full visibility of drug contents

Automatic insertion, delivery and retraction
of the needle

Single push-button activation

Designed for simple assembly of the syringe
into the Auto-Injector

A robust system designed to overcome PFS
variability issues

Auto Injection System Animation

AUTO INJECTION SYSTEM
VIDEO

Safety and Administration Systems

Market focus: entire injectable market

Needle-phobia

Patient and caregiver safety

OSHA and local EU legislation

Patient and caregiver convenience

West innovations

Reconstitution and transfer systems

Vial adaptors

Transfer aids

Safety needles

Project Orion passive safety system Q4

Kitting

Project Orion: What Does It Offer?

Passive, automatic needle cover

Compact design

Simple and easy to use

Compatible with any standard luer
lock syringe

Minimize patient fear! Minimal amount
of needle exposed

Project Orion

ORION VIDEO

Safety Test

SAFETY VIDEO

Prefillable Syringe Systems

Global PFS units

1.8B units

North America .3M units

Europe (E5)  1.5B units

CAGR 8-12%

Biologic market needs

Drug waste

Drug stability

Silicone, tungsten, adsorption

User convenience and self- administration

Prefillable Syringe Systems

RU Daikyo Crystal Zenith luer lock
syringe: Q2 2008

RU Daikyo Crystal Zenith staked
needle:  2009

Platform to Market Alignment

^{STRATEGIC
PLATFORMS}

^MARKET

^NEEDS

Patient or

Healthcare Worker

Pharmaceutical Customer

Injectable Container Systems

Safety and Administration Sys.

Prefillable Syringe Systems

Advanced Injection Systems

Value of West Products in the
Injectable Drug Package

Daikyo Crystal Zenith
Syringe System with
Orion

West auto injector

with Daikyo

Crystal Zenith

syringe

Bernie Lahendro

Vice President

and General Manager

Daikyo Crystal Zenith^® Products

Daikyo Seiko, Ltd.

Daikyo

Family-owned business since 1954

Approximately 500 employees and approximately $110 million U.S.D.

Market leader in Japan for pharmaceutical closures

Daikyo and West Partnership

West purchased 25% of Daikyo Seiko Ltd. in 1973

Technology transfer and marketing agreement signed in 1992 with additional 10
year agreements signed in 1997 & 2007

Daikyo has developed and transferred to West state of the art materials and
processes such as:

B2, Flurotec,  Daikyo Crystal Zenith

Flurotec material and B2 process technologies have been transferred to West

Ready-to-Use Crystal Zenith development programs are a cooperative effort of
Daikyo and West

Custom formulated COP resin
developed for pharmaceutical use

Coupled with Flurotec laminated
elastomers for low extractables with
no silicone oil

100% vision inspected

Platform for development of new
innovative products

Daikyo Crystal Zenith

Properties of Daikyo Crystal Zenith

Cyclic Polyolefin

Custom formulated for better break resistance,
scratch resistance and steam sterilizability

Exclusivity for Daikyo/West

High transparency

Colorless

Approved In All Major Markets

Japan

10  syringes: contrast media (5) MRI (2), hyaluronic
acid (2), calcitonin (1 - PEPTIDE)

3 vials: Fluconazole, oncology, anticoagulant

API container (one liter bottle)

US

3 vials: acyclovir and oncology, 1 syringe for
hyaluronic acid;  several pending for oncology,
cancer vaccine

Europe

1 syringe: hyaluronic acid

3 vials: oncology; several pending for oncology,
contrast imaging, blood plasma

Daikyo Crystal Zenith Syringe Systems

Sizes available from 0.25 mL to 150 mL

Daikyo Crystal Zenith1mL-S
RU Luer Lock Syringe System

Daikyo Crystal Zenith barrel

Polypropylene rod

Flurotec laminated piston

Flurotec lamination inside nozzle cap

Silicone oil free

100% vision inspected

Daikyo Crystal ZenithRU Syringe System
Features and Benefits

Provides market differentiation

Less adsorption/absorption

Predictable piston release and travel forces

Suitable for high viscosity products

Ultra low extractables

Reduces aggregation issues

No need for added silicone oil

Tungsten-free

Can be incinerated, eliminating disposal issues
related to blood borne pathogens

Flurotec Coverage Syringe

Complete coverage of
inert film on drug
contact surfaces

Orange color indicates Flurotec^® film coverage

Formula D-21-6-1 Ultra clean chlorobutyl

Plunger

Tip Cap

Daikyo Crystal Zenith 1ml LL-S
RU Syringe Systems

Ready for sampling

Launch April 2008

Sterilization:

Assembled syringes:

E-beam

Pistons: steam

Tubs and nests manufactured in
clean rooms

10 * 10 nest format for standardized
filling machines

Nested or bulk pistons

Model Antibody

Higher extent of aggregation in glass

compared to Daikyo Crystal Zenith ^®

Crystal Zenith

Glass

With Permission of the University of Kansas

Targeted Therapeutic Categories
Luer Lock Syringes

Large Molecules

Oncology

New Vaccines

Ophthalmic - Macular

Degeneration/Cataract

Surgery

Cosmeceuticals

Anti-Parkinsons

Anti-Alzheimers

Daikyo Crystal Zenith Ready-to-Use Staked Needle Syringe
(in development)

Silicone oil-free container

Reduced variability

Consistent piston release and
travel forces

Tungsten free

Glue free

Break resistant

Tight dimensional tolerances

Design flexibility of plastics

Targeted Therapeutic Categories
Staked Needle Syringes

Large Molecules

ESA

Auto-Immune,
MS

Anti-
Rheumatics

Hepatitis C

Daikyo Crystal Zenith^® Summary

First in silicone oil free prefillable syringes

Break resistant

Ultra low levels extractables/leachables/particulate

100% vision inspected (all components of syringe)

Zero defects for the high quality markets (Japan)

Protein aggregation - dramatic reductions

Tungsten, glue, silicone oil free staked needle syringes

Reduced need to reformulate

Low temperature storage opportunity

Steve Ellers

President & Chief Operating Officer

Delivering Innovative Solutions

Create profitable and sustainable growth platform

Strengthen market leadership position

Maintain strong financial condition

Strategic Objectives

Business Perspective

Market Position

Profit Margin

Operations

Pipeline

Sales

Business Perspective

Losing share

Market Position

Declining

Profit Margin

Aged & inadequate
factories

Operations

Re-launch old
products

Pipeline

Losing share

Sales

1995 - 2001

Business Perspective

Gaining momentum

Losing share

Market Position

Strong incremental gains

Declining

Profit Margin

Upgrade & catch-up
expansions

Aged & inadequate
factories

Operations

New product launches

Re-launch old
products

Pipeline

Listening and reacting to
customer

Losing share

Sales

2002 - 2006

1995 - 2001

Business Perspective

Leading market in
injectable container  
solutions

Gaining momentum

Losing share

Market Position

Funding growth
strategies compress
margins

Strong incremental gains

Declining

Profit Margin

Centers of Excellence

Upgrade & catch-up
expansions

Aged & inadequate
factories

Operations

Innovation & new
growth platforms

New product launches

Re-launch old
products

Pipeline

Creating solutions &
advising customers

Listening and reacting to
customer

Losing share

Sales

2007 - 2012

2002 - 2006

1995 - 2001

Market Knowledge Identifies Market Needs

Manufacturing Strategy

Capital Expenditures

Product Launches

Strengthen Sales and Market Penetration

Market segments

Diabetes, oncology, vaccines and generics

Long-term contracts

BD, Braun, Hospira, Consort, Covidien, Novo

Value-added (revenues 2x unit growth)

FluroTec, Westar,Daikyo, Envision, Spectra

2008 Product Pipeline

Q4

Q4

RSV (Daikyo)

Q4 ‘07

Q4

Envision

- - -

Q2

Inhalation/Nasal Lab Testing

Q2

Q2

RU Crystal Zenith Syringe System   (1 mL LL)

Q4

Q2

WestRU Ready Pack System

Europe

North

America

Targeted Market Launches

2008 Product Pipeline

Q4

Q4

Orion SQ

Q2

TBD

Westar RS Lined Seals

Q3

Q3

Auto-injector (P2 version)

Q2

Q2

RU PFS Plunger (non-nested)

- - -

Q2

Kitting Capability to Support SAS

Q2

Q2

Vented Vial Adapter

Europe

North

America

Targeted Commercial Introduction

Sales & Pipeline

Core – Growth Platforms

Injectable Container Solutions

Safety & Admin System

Prefillable Syringe System

Advanced Injection System

Safety

Orion

Medimop

Market Needs

Silicone-free

Daikyo Crystal Zenith

PFS

Systems Solution

Westar® - RU

Lined Seals

Ready Pack

Kitting

Reconstitution     

Regulatory

Verisure

CCS

TrimTec®

Material Science/drug contact

Quality

Vision Inspection

cGMP

Demographics/Convenience

Auto-injectors

Reconstitution

Close to our Knitting

Creative Access to New
Products and Solutions

Target

Mkt. Launch/ Comm.
Intro

Partners

Action

Market Need

Creative Access to New
Products and Solutions

CAGR 20%

Medimop

Acquire

Reconstitution

Target

Mkt. Launch/ Comm.
Intro

Partners

Action

Market Need

Creative Access to New
Products and Solutions

Q4

Salvus Tech

License

Safety

CAGR 20%

Medimop

Acquire

Reconstitution

Target

Mkt. Launch/ Comm.
Intro

Partners

Action

Market Need

Creative Access to New
Products and Solutions

Q2

Daikyo

Partner

PFS in RU Crystal
Zenith

Q4

Salvus Tech

License

Safety

CAGR 20%

Medimop

Acquire

Reconstitution

Target

Mkt. Launch/ Comm.
Intro

Partners

Action

Market Need

Creative Access to New
Products and Solutions

Q3

Pharma-Pen

Acquire &

in-house Develop

Auto-injector

Q2

Daikyo

Partner

PFS in RU Crystal
Zenith

Q4

Salvus Tech

License

Safety

CAGR 20%

Medimop

Acquire

Reconstitution

Target

Mkt. Launch/ Comm.
Intro

Partners

Action

Market Need

Market Knowledge Identifies Market Needs

Manufacturing Strategy

Capital Expenditures

Product Launches

Manufacturing Strategy

Focused factories – Centers of Excellence

Pharma and device facilities

Products manufactured to a global quality standard

Vision inspection

Six Sigma

Westar RS & RU

cGMP facilities with DMF registrations and FDA audits

Multiple site sourcing

Project Atlas

SAP and MES systems integration

Operate as cost centers

Market Knowledge Identifies Market Needs

Manufacturing Strategy

Capital Expenditures

Product Launches

Investments in Operations

Europe and Asia Expansion Projects

China Greenfield

China plastics in Qingpu

USA Expansions

IT Project Atlas – SAP and MES

Jurong,

Singapore

Bodmin,
England

Kovin,
Serbia

LeNouvion,
France

Eschweiler,
Germany

Jersey Shore,

Pennsylvania

Clearwater,

Florida

Kinston,

North Carolina

Capital

as % of sales10%8%12%          10% 7%10%13%14%

Depreciation

as % of sales7%7% 6%6%6%5% 5%6%

Operations Record Levels of CAPEX

Manufacturing Processes

Rubber

Compounding           Molding           Trimming   Finishing

Specialty products

Metal

TrimTec

Compounding

Molding

Trimming

Washing/Finishing

Vision Inspection

Metals

TrimTec

Market Knowledge Identifies Market Needs

Manufacturing Strategy

Capital Expenditures

Product Launches

Product Launch Process

Match need in market with West product

Target specific customers

Secure development partnerships

Sampling

Machine trials

Stability tests

Regulatory assistance

Analytical Labs

Product Launch Process

Plan – Initiate Launch Campaign

CAPEX investments

Promotion

Training

Sample kits

Broad market - product launch (2 - 3 years later)

Market experience

Market acceptance/regulatory approval

Customer ramp-ups

Product Launches

Westar RS

Elastomer components

Seals

Westar Units Sold in North America
(in millions)

Product Launches

Drive development through superior positioning

FluroTec

Unrivaled

barrier

coating

Westar

State of the art
ready-to-sterilize
elastomer closures

Flip-OffCCS

Prewashed and

sterilized Flip-Off
seals

West Spectra

Covert and overt
security for product
authentication

Branding of Value-Added
Products & Services

West Analytical Services

Tech Restructuring
(December 2007)

Pfizer decision to abandon Exubera

Need to right-size operations

Accelerate transition to IP-based systems supplier

Tech Restructuring Activities

Close Erie, PA tool shop

Right size SG&A and Engineering

Mexico - transfers

Mold moves to create “focused factories”

Grand Rapids turnaround

Strategic Business Units

Organize SBU’s around markets

Consumer

Health Care

Device Systems

General Managers with P&L responsibilities

Improved profitability

Allocation of resources

Provide integrated approach to serve customers

Invest CAPEX based on market/strategic plan

Shed unprofitable business

Tech Group Synergies

Manufactured

by Tech

Product/ Market

Partner

Growth Platform

Tech Group Synergies

Reconstitution

Medimop

Safety & Admin.
Systems

Manufactured

by Tech

Product/ Market

Partner

Growth Platform

Tech Group Synergies

Orion Safety Needle

Salvus Tech

Safety & Admin.
Systems

Reconstitution

Medimop

Safety & Admin.
Systems

Manufactured

by Tech

Product/ Market

Partner

Growth Platform

Tech Group Synergies

Orion Safety Needle

Salvus Tech

Safety & Admin.
Systems

Unique Silicone Oil
Free, Tungsten Free

Syringe System

Daikyo Crystal
Zenith

Prefillable Syringe
Systems

Reconstitution

Medimop

Safety & Admin.
Systems

Manufactured

by Tech

Product/ Market

Partner

Growth Platform

Tech Group Synergies

Orion Safety Needle

Salvus Tech

Safety & Admin.
Systems

Auto Injector

In-house with
Pharma-Pen

Advanced Injection

Unique Silicone Oil
Free, Tungsten Free

Syringe System

Daikyo Crystal
Zenith

Prefillable Syringe
Systems

Reconstitution

Medimop

Safety & Admin.
Systems

Manufactured

by Tech

Product/ Market

Partner

Growth Platform

Tech Direction

Transition to proprietary intellectual property (IP)

Synergies with Innovation and core Pharmaceutical Systems

Conversion from component to systems provider

Summary

Strengthen market leadership position

Grow faster than market

Record number of product introductions

Sufficient cash flow to fund CAPEX and R&D

Accelerate innovation activities:

In-house R&D

Licensing

Strategic partnering

Acquisitions

Attractive opportunities to expand geographically

Synergies of core business with Tech and Innovation create a bright
future

Summary

Delivering Innovative Solutions

Don Morel

Chairman and Chief Executive Officer

Grow revenues and earnings

despite reduced sales of certain products

Organic growth and sales mix will offset lost revenue
associated with Exubera, ESA drugs etc.

Offset cost increases (raw materials, labor, energy) with lean
programs, operating efficiencies and pricing

Generate Tech Group performance improvement

New Grand Rapids facility recovery from 2007 relocation and
expansion

Execute restructuring of operating footprint

Shift product mix: focus on healthcare and proprietary products

Effectively manage global capacity expansion

Monitor relevant changes in demand, lead times

Timely availability of increased capacity

Management Operating Priorities
2008 - 2012

Continue Investing for the future

Innovation programs

Aggressive launch schedule

Geographic expansion plans - China, India

IT Platforms

Management Operating Priorities
2008 - 2012

Investment Considerations

Established foundation for sustainable growth

Significant barriers to entry

Favorable growth drivers in key market segments

Global, diverse customer base

Global manufacturing capability

Strong, experienced management team

Strong corporate governance

2008 Annual Guidance

Revenue estimated between $1.05 and $1.07 billion

Estimated adjusted earnings per diluted share is between $2.40
and $2.50.  This estimate:

Excludes anticipated restructuring costs of an approximately $8.6 million

Includes exchange rate assumption of $1.40/1 Euro

Includes between $50 million and $60 million of lower revenue estimates
compared to 2007 and associated with specific customer products,
including Exubera^®, ESA drugs and diagnostic device components, which
should adversely impact operating profit by approximately 35% of the
revenue impact

2008 Annual Guidance

Lower revenues from those specified products will have a much
more pronounced impact on periodic comparisons to 2007
during the first half of 2008

Specified products contributed earnings per diluted share of $0.14 in the
first quarter and $0.11 in the second quarter of 2007, as those periods
predated events affecting sales of those products

Impact on comparisons should diminish through the year as other sales
growth is expected to begin to offset and ultimately exceed revenue
losses

Five-Year Financial Goals

Expect average annual sales growth of between 7% and 9%, excluding  
acquisitions

Growth in existing products, supported by capacity expansions, in the near- term

New products and geographic expansion contribute significantly beginning in
2010.

Operating profit growth should average between 10% and 12% per year

Sales mix should continue to improve on existing products,

Lean operations, ability to pass on commodity and energy costs, and operating
leverage are expected to protect and improve margins,

New products are expected to further enhance sales mix and profitability.

Five-Year Financial Goals

Continue to manage balance sheet and capital conservatively

Maintain net debt to total capital ratio between 30% and 40%,
excluding acquisitions

Acquisition activity focused on complementary, proprietary
products

Summary

Working through short-term revenue challenges

Long term business drivers remain in place

Strategic Product Platforms create sustainable growth opportunities

West’s competitive advantages uniquely position the Company to
capitalize on these opportunities:

Daikyo partnership

Global manufacturing footprint

Proprietary technology and systems

Strong regulatory barriers

Industry leading knowledge on drug – material interface

Solid balance sheet

Management incentives directly linked to value creation

GAAP and Adjusted EPS
2007

Diluted earnings per share from continuing operations

As reported$2.06

Restructuring, impairment and other charges0.54

Tax adjustments/settlements(0.23)

As Adjusted$2.37

Our reported 2007 results include the impact of restructuring charges, an impairment loss on our
customer contract intangible asset with Nektar for the Exubera® device, and our provisions for
Brazilian tax issues which collectively totaled $26.4 million pre-tax ($19.4 million net of tax, or $0.54
per diluted share). Our 2007 results also include the recognition of discrete tax benefits totaling $8.2
million ($0.23 per diluted share).

Adjusted results are intended to aid investors in understanding the Company’s results absent non-
recurring or unusual events and are non-GAAP financial measures.

Investor Day 2008